← All Bionano Genomics, INC filings

Bionano Genomics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
BNGO
Bionano Genomics, INC
10-K: Bionano Genomics Narrows Losses, Faces Ongoing Going Concern Doubt
Bionano Genomics reported a significant reduction in net losses for 2025, driven by cost-saving initiatives, but faces ongoing substantial doubt about its ability to continue as a going concern without further capital.
NASDAQ
BNGO
Bionano Genomics, INC
10-K: Bionano Genomics Reports Full Year 2024 Results, Focuses on OGM Adoption
Bionano Genomics reports a 15% decrease in total revenue for 2024, shifting focus to installed base utilization and cost savings.
NASDAQ
BNGO
Bionano Genomics, INC
10-K: Bionano Genomics 10-K Filing: Focus on OGM Growth and Financial Challenges
Bionano Genomics' 10-K filing highlights the company's focus on optical genome mapping (OGM) technology, commercial expansion, and ongoing financial challenges.